Cullinan Oncology Property Plant Equipment Over Time
| CGEM Stock | USD 13.09 0.32 2.51% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cullinan Oncology Performance and Cullinan Oncology Correlation. Cullinan |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Property Plant Equipment Analysis
Compare Cullinan Oncology LLC and related stocks such as Bolt Biotherapeutics, Day One Biopharmaceu, and Lyra Therapeutics Property Plant Equipment Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BOLT | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 11.5 M | 16.4 M | 30.6 M | 28.5 M | 32.8 M | 19.5 M |
| DAWN | 483 K | 483 K | 483 K | 483 K | 483 K | 483 K | 483 K | 483 K | 483 K | 483 K | 483 K | 57 K | 20 K | 18 K | 17.1 K |
| LYRA | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 3.4 M | 2.2 M | 5.9 M | 4.5 M | 5.1 M | 3.5 M |
| AUTL | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 605.3 K | 3.3 M | 6.2 M | 20 M | 51.6 M | 89.7 M | 52.3 M | 58.4 M | 67.2 M | 36.1 M |
| SANA | 585 K | 585 K | 585 K | 585 K | 585 K | 585 K | 585 K | 585 K | 585 K | 68.8 M | 109.9 M | 65.5 M | 66.9 M | 77 M | 68.6 M |
| OLMA | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 75 K | 4.7 M | 1.5 M | 1.7 M | 1.4 M |
| ZNTL | 260 K | 260 K | 260 K | 260 K | 260 K | 260 K | 260 K | 260 K | 260 K | 2.8 M | 3.6 M | 8.1 M | 7.7 M | 8.9 M | 5 M |
| IPSC | 440.9 M | 440.9 M | 440.9 M | 440.9 M | 440.9 M | 440.9 M | 402.1 M | 2.5 M | 2.5 M | 2.5 M | 24.8 M | 58 M | 82.8 M | 74.5 M | 134.8 M |
| EWTX | 498 K | 498 K | 498 K | 498 K | 498 K | 498 K | 498 K | 498 K | 498 K | 498 K | 516 K | 912 K | 8.5 M | 9.8 M | 10.3 M |
| CCCC | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 18.9 M | 16.6 M | 3.1 M | 7.4 M | 6.7 M | 10.6 M |
| VOR | 71 K | 71 K | 71 K | 71 K | 71 K | 71 K | 71 K | 71 K | 71 K | 728 K | 21.8 M | 6.9 M | 12.6 M | 14.5 M | 9.3 M |
| LYEL | 43.7 M | 43.7 M | 43.7 M | 43.7 M | 43.7 M | 43.7 M | 43.7 M | 43.7 M | 43.7 M | 43.7 M | 124.1 M | 120.1 M | 166.3 M | 191.2 M | 124.9 M |
| GLUE | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 4.6 M | 12.3 M | 27.1 M | 31.1 M | 32.7 M |
| RVMD | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 6.9 M | 7.1 M | 8.9 M | 71.2 M | 73.7 M | 84.8 M | 89 M |
Cullinan Oncology LLC and related stocks such as Bolt Biotherapeutics, Day One Biopharmaceu, and Lyra Therapeutics Property Plant Equipment description
My Equities
My Current Equities and Potential Positions
| Cullinan Oncology LLC | CGEM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 13.09
Check out Cullinan Oncology Performance and Cullinan Oncology Correlation. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Cullinan Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.